German drug discovery company Evotec AG believes it may have hit upon a new model for industry-academia research collaborations in its year-old tie-up with the Harvard University laboratory of Prof. Douglas Melton.
Not only has their "CureBeta" initiative on regenerating insulin-producing beta-cells in type 1 and type 2 diabetes found a new...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?